Dr. Lajonchere is the Deputy Director for the UCLA Institute for Precision Health and Adjunct Professor in the Department of Neurology at the David Geffen School of Medicine at UCLA. Her background reflects a wide range of professional, clinical, and research experience across CNS disorders. She has spent her career on cross-cutting issues in psychiatric genetics and translational medicine. Through the Institute, Dr. Lajonchere worked collaboratively with thought leaders across the state of California to advance precision medicine and improve outcomes for patients. Prior to UCLA, Dr. Lajonchere held faculty appointments at USC where she conducted her own NIH research, and served as VP of Clinical Programs for Autism Speaks. More recently, she served as the Chief Scientific Officer for Cognoa, Inc, a digital healthcare company in Palo Alto and consults for several tech start-ups in the autism space focused on AI, robotics, and targeted therapeutics.
Recently, several unique partnerships for population sequencing studies have been launched. Various medical organizations and pharmaceutical and direct-to-consumer testing companies are included in these partnerships. The designed studies are expected to create new insights, identify new disease targets, and improve individualized patient care. In this session we will hear updates about several of these collaborative population studies to learn about the various opportunities created, the resulting benefits for each of the partners, and the challenges that need to be overcome in relation to data flow and data sharing.